Johnson & Johnson’s prostate cancer drug Zytiga (abiraterone) now has a label that reflects a statistically significant overall survival benefit in the important earlier-stage population of chemotherapy-naïve metastatic prostate cancer patients.
FDA approved a new label for the androgen receptor inhibitor when used with prednisone citing this advantage in chemo-naïve metastatic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?